company background image
IVIX.F logo

Invion OTCPK:IVIX.F Stock Report

Last Price

US$0.05

Market Cap

US$11.2m

7D

0%

1Y

n/a

Updated

23 Dec, 2024

Data

Company Financials

IVIX.F Stock Overview

A clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. More details

IVIX.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Invion Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Invion
Historical stock prices
Current Share PriceAU$0.05
52 Week HighAU$0.50
52 Week LowAU$0.05
Beta1.29
1 Month Change-77.27%
3 Month Changen/a
1 Year Changen/a
3 Year Change-96.43%
5 Year Change-95.00%
Change since IPO-99.17%

Recent News & Updates

Recent updates

Shareholder Returns

IVIX.FUS PharmaceuticalsUS Market
7D0%-0.3%-2.7%
1Yn/a7.9%23.4%

Return vs Industry: Insufficient data to determine how IVIX.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how IVIX.F performed against the US Market.

Price Volatility

Is IVIX.F's price volatile compared to industry and market?
IVIX.F volatility
IVIX.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: IVIX.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IVIX.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aThian Chewwww.inviongroup.com

Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.

Invion Limited Fundamentals Summary

How do Invion's earnings and revenue compare to its market cap?
IVIX.F fundamental statistics
Market capUS$11.17m
Earnings (TTM)-US$3.52m
Revenue (TTM)US$2.31m

4.8x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVIX.F income statement (TTM)
RevenueAU$3.69m
Cost of RevenueAU$2.69m
Gross ProfitAU$1.00m
Other ExpensesAU$6.63m
Earnings-AU$5.63m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.082
Gross Margin27.16%
Net Profit Margin-152.34%
Debt/Equity Ratio0%

How did IVIX.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:48
End of Day Share Price 2024/12/12 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Invion Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution